Last reviewed · How we verify
dapagliflozin and saxagliptin
dapagliflozin and saxagliptin is a Sodium-Glucose Cotransporter 2 Inhibitor [EPC] Small molecule drug developed by AstraZeneca. It is currently FDA-approved for Glycemic Control in Type 2 Diabetes. Also known as: QTERN Tablet.
Dapagliflozin and saxagliptin, marketed by AstraZeneca, is a combination therapy for glycemic control in type 2 diabetes. The key composition patent expires in 2028, providing a strong barrier to generic competition until then. The primary risk is the intense competition in the type 2 diabetes market, which could impact market share and revenue.
At a glance
| Generic name | dapagliflozin and saxagliptin |
|---|---|
| Also known as | QTERN Tablet |
| Sponsor | AstraZeneca |
| Drug class | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Glycemic Control in Type 2 Diabetes
Common side effects
- Urinary tract infection
- Genital mycotic infections
- Impairment of renal function
- Upper respiratory tract infection
- Dyslipidemia
Serious adverse events
- Severe hypoglycemia
- Volume depletion (hypotension, dehydration, hypovolemia)
- Hypoglycemia
- Pyelonephritis
Key clinical trials
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
- Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) (NA)
- SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.
- Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers (PHASE2, PHASE3)
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients (PHASE4)
- Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dapagliflozin and saxagliptin CI brief — competitive landscape report
- dapagliflozin and saxagliptin updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about dapagliflozin and saxagliptin
What is dapagliflozin and saxagliptin?
What is dapagliflozin and saxagliptin used for?
Who makes dapagliflozin and saxagliptin?
Is dapagliflozin and saxagliptin also known as anything else?
What drug class is dapagliflozin and saxagliptin in?
What development phase is dapagliflozin and saxagliptin in?
What are the side effects of dapagliflozin and saxagliptin?
Related
- Drug class: All Sodium-Glucose Cotransporter 2 Inhibitor [EPC] drugs
- Manufacturer: AstraZeneca — full pipeline
- Indication: Drugs for Glycemic Control in Type 2 Diabetes
- Also known as: QTERN Tablet
- Compare: dapagliflozin and saxagliptin vs similar drugs
- Pricing: dapagliflozin and saxagliptin cost, discount & access